Fingerprint
Dive into the research topics of 'Phase II trial of esorubicin (4′deoxydoxorubicin, DxDx) in patients with small cell lung cancer'. Together they form a unique fingerprint.- Sort by
- Weight
- Alphabetically
Phase II trial of esorubicin (4′deoxydoxorubicin, DxDx) in patients with small cell lung cancer
James R. Rigas, Mark G. Kris, Richard J. Gralla, Robert T. Heelan, Linda D. Marks
Research output: Contribution to journal › Article › peer-review
2
Scopus
citations